Navigation Links
Profil Institute Continues to Publish New Findings in Metabolic Research
Date:3/21/2012

SAN DIEGO, March 21, 2012 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a company focused on early phase clinical trials for diabetes and obesity, announced today its continued focus on contributing to scientific research in the public domain. The company published research on new therapies in diabetes in nine scientific journals last year and one of its key scientists Prof. Andrew Krentz has authored two textbooks on drug therapy for type 2 diabetes, due to publish this summer.

"We are in a notable position of having been involved in clinical research in almost every promising diabetes-related therapy and in all key anti-diabetic drug categories, benefiting diabetes research as a whole," said Dr. Marcus Hompesch, Profil Institute CEO. "Profil Institute's scientists hail from the world's most renowned institutes and universities focused on diabetes and other metabolic disorders, and we believe strongly in continuing to contribute to the advancement of scientific research in the public domain." 

A list of the company's most recent publications is available on Profil Institute's website www.profilinstitute.com under Scientific Expertise with abstracts or full articles available at the US National Library of Medicine's website www.pubmed.gov

Scientific journals include Journal of Diabetes Science and Technology; Diabetes Technology and Therapeutics; Diabetes, Obesity and Metabolism; Diabetes Care; and Treatment Strategies Diabetes.

The two textbooks Drug Therapy for Type 2 Diabetes (London: Adis, 2012, in press) and Pharmacotherapy for Type 2 Diabetes (London: Royal Society of Medicine Press, 2012, in press) are authored by Prof. Andrew Krentz, Profil Institute's Senior Director of Scientific Services.

The textbooks present detailed coverage of established glucose-lowering drugs and recently-introduced therapy options for type 2 diabetes.  Most notably for physicians, the textbooks discuss how to integrate newer drugs in the context of established drug therapy, guidelines and treatment algorithms. Both textbooks are expected to publish later this summer.

About Profil® Institute for Clinical Research, Inc.

Profil Institute's advances in early phase drug research and its specific focus on diabetes, obesity and cardiometabolic diseases as it relates to the diabetic patient population have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials. 

To date, Profil Institute has been involved with almost every clinically promising drug category and device development in diabetes and in more than 175 clinical studies since the company's inception in 2004. Contributing to Profil Institute's success is that the company is recognized as the leader in automated glucose clamps, considered the "Gold Standard" for the evaluation of anti-diabetic drugs and devices.  The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Dusseldorf, Columbia University, University of Michigan and Harvard University. For more information visit www.profilinstitute.com.

 

 


'/>"/>
SOURCE Profil Institute for Clinical Research, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Profiler at the cellular level
2. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
3. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
4. Precision Therapeutics Announces New Tumor Profiling Product to Augment Utility of ChemoFx® and Further Personalize Cancer Treatment
5. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
6. Reportlinker Adds Merck KGaA: PharmaVitae Profile
7. Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome
10. DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
11. Profil Institutes Dr. Marcus Hompesch Named Finalist in Ernst & Young Entrepreneur Of The Year(R) 2010 Award for Second Year in a Row
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Alex,s Lemonade Stand Foundation (ALSF), ... it will open a state-of-the-art bioinformatics lab, using ,big ... This announcement comes as Liz Scott , co-executive ... Cancer Moonshot Summit in Washington, D.C. ... a participant and advocate of pediatric cancer research and ...
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):